144 related articles for article (PubMed ID: 38018862)
1. Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?
Williams AD; Ruth K; Shaikh SS; Vasigh M; Pronovost MT; Aggon AA; Porpiglia AS; Bleicher RJ
Cancer; 2024 Apr; 130(7):1052-1060. PubMed ID: 38018862
[TBL] [Abstract][Full Text] [Related]
2. A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy.
Yang H; Sun Y; Wang P; Qiao J; Li L; Lu Z; Sun X; Zhang C; Chen X; Yan M; Cui S; Wang C; Liu Z
Med Sci Monit; 2023 Jul; 29():e940124. PubMed ID: 37454245
[TBL] [Abstract][Full Text] [Related]
3. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
[TBL] [Abstract][Full Text] [Related]
4. Does ultrasound evaluation of the axilla increase the rate of axillary lymph node dissection in early stage clinically node negative breast cancer patients?
Vasigh M; Meshkati Yazd SM; Karoobi M; Hajebi R; Yazdankhah Kenari A
BMC Surg; 2022 Mar; 22(1):80. PubMed ID: 35241059
[TBL] [Abstract][Full Text] [Related]
5. To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?
Farley C; Bassett R; Meric-Bernstam F; Bedrosian I; Caudle A; DeSnyder S; Hunt K; Kuerer H; Singh P; Sun S; Tamirisa N; Teshome M; Hwang RF
Ann Surg Oncol; 2023 Dec; 30(13):8327-8334. PubMed ID: 37670121
[TBL] [Abstract][Full Text] [Related]
6. Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes.
Kantor O; Weiss A; Burstein HJ; Mittendorf EA; King TA
Ann Surg Oncol; 2022 Nov; 29(12):7674-7682. PubMed ID: 35763229
[TBL] [Abstract][Full Text] [Related]
7. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
8. Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib.
Gaillard T; Piketty J; Feron JG; Girard N; Pauly L; Gauroy E; Darrigues L; Grandal B; Pierga JY; Hamy-Petit AS; Reyal F; Laas E
Br J Cancer; 2024 Apr; 130(7):1141-1148. PubMed ID: 38280968
[TBL] [Abstract][Full Text] [Related]
9. Independent risk factors for axillary lymph node metastasis in breast cancer patients with one or two positive sentinel lymph nodes.
Zhang W; Xu J; Wang K; Tang XJ; Liang H; He JJ
BMC Womens Health; 2020 Jul; 20(1):143. PubMed ID: 32646416
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a pre- and intra-operative scoring system that distinguishes between non-advanced and advanced axillary lymph node metastasis in breast cancer with positive sentinel lymph nodes: a retrospective study.
Murata T; Watase C; Shiino S; Kurita A; Ogawa A; Jimbo K; Iwamoto E; Yoshida M; Takayama S; Suto A
World J Surg Oncol; 2022 Sep; 20(1):314. PubMed ID: 36171615
[TBL] [Abstract][Full Text] [Related]
11. Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes.
Prathibha S; White M; Kolbow M; Hui JYC; Brauer D; Ankeny J; Jensen EH; LaRocca CJ; Marmor S; Tuttle TM
Breast Cancer Res Treat; 2024 May; 205(1):127-133. PubMed ID: 38281296
[TBL] [Abstract][Full Text] [Related]
12. Locoregional Management of the Axilla in Mastectomy Patients with One or Two Positive Sentinel Nodes: The Role of Intraoperative Pathology.
Davis J; Boughey JC; Hoskin TL; Day CN; Cheville JC; Piltin MA; Hieken TJ
Clin Breast Cancer; 2021 Oct; 21(5):458-465. PubMed ID: 33839043
[TBL] [Abstract][Full Text] [Related]
13. Predictors of non-sentinel lymph node metastasis in breast cancer patients.
Goyal A; Douglas-Jones A; Newcombe RG; Mansel RE;
Eur J Cancer; 2004 Jul; 40(11):1731-7. PubMed ID: 15251163
[TBL] [Abstract][Full Text] [Related]
14. Factors Influencing Non-sentinel Lymph Node Involvement in Patients with Positive Sentinel Lymph Node(s) After Neoadjuvant Chemotherapy for Breast Cancer.
Sanders SB; Hoskin TL; Stafford AP; Boughey JC
Ann Surg Oncol; 2022 Nov; 29(12):7769-7778. PubMed ID: 35834142
[TBL] [Abstract][Full Text] [Related]
15. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
16. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
17. Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes.
Aragon-Sanchez S; Oliver-Perez MR; Madariaga A; Tabuenca MJ; Martinez M; Galindo A; Arroyo ML; Gallego M; Blanco M; Ciruelos-Gil EM
Breast J; 2022; 2022():1507881. PubMed ID: 36051467
[TBL] [Abstract][Full Text] [Related]
18. The involvement of axillary reverse mapping nodes in patients with clinically node-negative breast cancer.
Noguchi M; Inokuchi M; Yokoi-Noguchi M; Morioka E
Breast Cancer; 2022 Mar; 29(2):209-215. PubMed ID: 34591289
[TBL] [Abstract][Full Text] [Related]
19. Prediction of additional lymph node involvement in breast cancer patients with positive sentinel lymph nodes.
Pohlodek K; Bozikova S; Meciarova I; Mucha V; Bartova M; Ondrias F
Neoplasma; 2016; 63(3):427-34. PubMed ID: 26925789
[TBL] [Abstract][Full Text] [Related]
20. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
Yoo TK; Kang BJ; Kim SH; Song BJ; Ahn J; Park WC; Chae BJ
Breast Cancer Res Treat; 2020 Jun; 181(2):403-409. PubMed ID: 32328848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
